Biogen-backed Estuary nabs $93M for liver disease gene therapy

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 16 Oct, 10:30 UTC

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."

businessscience

Sources

• T2Biogen-backed Estuary nabs $93M for liver disease gene therapyBioPharma Dive / Healthcare Dive / MedTech Dive16 Oct, 10:30